参考文献
[1] Mullish BH, Pechlivanis A, Barker GF, et al. Functional microbiomics: Evaluation of gut microbiota-bile acid metabolism interactions in health and disease[J]. Methods, 2018，S104620231730422X.
[2] B?ckhed F, Ley RE, Sonnenburg JL, et al. Host-bacterial mutualism in the human intestine[J]. Science, 2005,307(5717):1915-1920.
[3] Tremaroli V, B?ckhed F. Functional interactions between the gut microbiota and host metabolism[J]. Nature, 2012,489(7415):242-249.
[4] Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions[J]. Science, 2012,336(6086):1262-1267.
[5] Wells JM, Rossi O, Meijerink M, et al. Epithelial crosstalk at the microbiota-mucosal interface[J]. Proc Natl Acad Sci U S A, 2011,108 Suppl 1:4607-4614.
[6] Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function[J]. Gastroenterology, 2007,132(4):1359-1374.
[7] Hida M, Aiba Y, Sawamura S, et al. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis[J]. Nephron, 1996,74(2):349-355.
[8] Vaziri ND, Wong J, Pahl M, et al. Chronic kidney disease alters intestinal microbial flora[J]. Kidney Int, 2013,83(2):308-315.
[9] Wang F, Zhang P, Jiang H, et al. Gut bacterial translocation contributes to microinflammation in experimental uremia[J]. Dig Dis Sci, 2012,57(11):2856-2862.
[10] Li J, Lin S, Vanhoutte PM, et al. Akkermansia Muciniphila Protects Against Atherosclerosis by Preventing Metabolic Endotoxemia-Induced Inflammation in Apoe-/- Mice[J]. Circulation, 2016,133(24):2434-2446.
[11] Szeto CC, Kwan BC, Chow KM, et al. Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients[J]. Clin J Am Soc Nephrol, 2008,3(2):431-436.
[12] Feroze U, Kalantar-Zadeh K, Sterling KA, et al. Examining associations of circulating endotoxin with nutritional status, inflammation, and mortality in hemodialysis patients[J]. J Ren Nutr, 2012,22(3):317-326.
[13] McIntyre CW, Harrison LE, Eldehni MT, et al. Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease[J]. Clin J Am Soc Nephrol, 2011,6(1):133-141.
[14] Szeto CC, Kwan BC, Chow KM, et al. Endotoxemia is associated with better clinical outcome in incident Chinese peritoneal dialysis patients: a prospective cohort study[J]. Perit Dial Int, 2010,30(2):178-186.
[15] Lin CJ, Chen HH, Pan CF, et al. p-Cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease[J]. J Clin Lab Anal, 2011,25(3):191-197.
[16] Dou L, Jourde-Chiche N, Faure V, et al. The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells[J]. J Thromb Haemost, 2007,5(6):1302-1308.
[17] Dou L, Sallée M, Cerini C, et al. The cardiovascular effect of the uremic solute indole-3 acetic acid[J]. J Am Soc Nephrol, 2015,26(4):876-887.
[18] Dou L, Cerini C, Brunet P, et al. P-cresol, a uremic toxin, decreases endothelial cell response to inflammatory cytokines[J]. Kidney Int, 2002,62(6):1999-2009.
[19] Meijers BK, Van Kerckhoven S, Verbeke K, et al. The uremic retention solute p-cresyl sulfate and markers of endothelial damage[J]. Am J Kidney Dis, 2009,54(5):891-901.
[20] Li T, Gua C, Wu B, et al. Increased circulating trimethylamine N-oxide contributes to endothelial dysfunction in a rat model of chronic kidney disease[J]. Biochem Biophys Res Commun, 2018,495(2):2071-2077.
[21] JAP T, Wheeler DC. The role of trimethylamine N-oxide as a mediator of cardiovascular complications in chronic kidney disease[J]. Kidney Int, 2017,92(4):809-815.
[22] Nakabayashi I, Nakamura M, Kawakami K, et al. Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study[J]. Nephrol Dial Transplant, 2011,26(3):1094-1098.
[23] Takayama F, Taki K, Niwa T. Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis[J]. Am J Kidney Dis, 2003,41(3 Suppl 1):S142-145.
[24] Borges NA, Stenvinkel P, Bergman P, et al. Effects of Probiotic Supplementation on Trimethylamine-N-Oxide Plasma Levels in Hemodialysis Patients: a Pilot Study[J]. Probiotics Antimicrob Proteins, 2018，s12602-018-9411-1
[25] Rossi M, Johnson DW, Morrison M, et al. Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A Randomized Trial[J]. Clin J Am Soc Nephrol, 2016,11(2):223-231.
[26] Wang IK, Wu YY, Yang YF, et al. The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: a randomised, double-blind, placebo-controlled trial[J]. Benef Microbes, 2015,6(4):423-430.
[27] Soleimani A, Zarrati MM, Bahmani F, et al. Probiotic supplementation in diabetic hemodialysis patients has beneficial metabolic effects[J]. Kidney Int, 2017,91(2):435-442.
[28] Viramontes-H?rner D, Márquez-Sandoval F, Martín-del-Campo F, et al. Effect of a symbiotic gel (Lactobacillus acidophilus + Bifidobacterium lactis + inulin) on presence and severity of gastrointestinal symptoms in hemodialysis patients[J]. J Ren Nutr, 2015,25(3):284-291.
